Literature DB >> 16322380

Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment.

Sefik Tagay1, Stephan Herpertz, Matthias Langkafel, Yesim Erim, Lutz Freudenberg, Nicole Schöpper, Andreas Bockisch, Wolfgang Senf, Rainer Görges.   

Abstract

OBJECTIVE: Very few previous studies have compared the degree of health-related quality of life (HRQL), depression and anxiety of differentiated thyroid cancer patients (DTC) under short-term hypothyroid-ism and levothyroxine treatment.
METHODS: Using patient-completed instruments, we examined the frequency of physical complaints, HRQL, anxiety and depression in 130 DTC patients hospitalized for radioiodine therapy or whole-body diagnostics (age 52 years, female 71%) under short-term hypothyroidism (4 weeks of levothyroxine withdrawal; DTC-H) and in 100 DTC out-patients under TSH-suppressive doses of levothyroxine subsequent to radioiodine therapy (DTC-L; age 49 years, female 81%).
RESULTS: Compared with the German general population, DTC-H as well as DTC-L patients had significantly impaired HRQL. Notably, the decrease in HRQL was significantly higher in DTC-H than in DTC-L patients. Surprisingly, the prevalence of anxiety (44.6%) but not depression (17.7%) was much higher in the DTC-H patients than in the general population. In contrast to expectations, similar results for anxiety (44.0%) and depression (17.6%) were observed in the DTC-L patients.
CONCLUSIONS: This mounting evidence suggests that a consistent pattern of HRQL impairment is experienced by patients with DTC. The high frequency of anxiety and the significantly reduced HRQL should be considered in the aftercare of DTC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322380     DOI: 10.1530/eje.1.02047

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  22 in total

1.  Assessment of physical etiologies for mood and anxiety disorders in structured diagnostic interviews.

Authors:  Scott B Patten; Jeanne V A Williams
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-04-21       Impact factor: 4.328

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Quality of life-in patients with differentiated thyroid cancer at the general endocrinology clinics of the University Hospital of Puerto Rico.

Authors:  Mónica A Vega-Vázquez; Loida Gonzalez-Rodriguez; Eduardo J Santiago-Rodríguez; Anette Garcés-Domínguez; Lee-Ming Shum; Maribel Tírado-Gómez; Margarita Ramírez-Vick
Journal:  Bol Asoc Med P R       Date:  2015 Jan-Mar

4.  Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients.

Authors:  Celestino Pio Lombardi; Raffaella Bocale; Angelina Barini; Antonella Barini; Annamaria D'Amore; Mauro Boscherini; Rocco Bellantone
Journal:  Endocrine       Date:  2016-07-07       Impact factor: 3.633

Review 5.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

6.  A Qualitative Analysis of the Preoperative Needs of Patients With Papillary Thyroid Cancer.

Authors:  Susan C Pitt; Elizabeth Wendt; Megan C Saucke; Corrine I Voils; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel
Journal:  J Surg Res       Date:  2019-07-12       Impact factor: 2.192

7.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

8.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

9.  The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition.

Authors:  Mary H Samuels; Irina Kolobova; Anne Smeraglio; Dawn Peters; Jeri S Janowsky; Kathryn G Schuff
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

Review 10.  Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival.

Authors:  Megan K Applewhite; Benjamin C James; Sharone P Kaplan; Peter Angelos; Edwin L Kaplan; Raymon H Grogan; Briseis Aschebrook-Kilfoy
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.